journal article·2018-10-31

Development and physicochemical, toxicity and immunogenicity assessments of recombinant hepatitis B surface antigen (rHBsAg) entrapped in chitosan and mannosylated chitosan nanoparticles: as a novel vaccine delivery system and adjuvant

Mohsen Mehrabi, Naser Mohammadpour Dounighi, Seyed Mahdi Rezayat Sorkhabadi, Delaram Doroud, Amir Amani, Mehdi Khoobi, Soheila Ajdary, Younes Pilehvar-Soltanahmadi

Publisher page

Abstract

In this study chitosan nanoparticles (CS NPs) and mannosylated chitosan nanoparticles (MCH NPs) loaded with recombinant hepatitis B surface antigen (rHBsAg) was synthesized as a vaccine delivery system and assessed toxically and immunologically. The physicochemical properties of the nanoparticles (NPs) were determined by methods including scanning electron microscope (SEM) and dynamic light scattering (DLS). The morphology of the NPs was semi spherical and the average diameter of the loaded CS and MCH NPs was found to be 189 and 239 nm, respectively. The release studies showed that after the initial burst, both of the loaded NPs provided a continuous and slow release of the antigens. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay showed concentration and time dependent toxicity profile for both formulations, but rHBsAg loaded CS nanoparticle showed higher toxicity due to smaller particle size and larger zeta potential. Abnormal toxicity test (ATT) results showed no signs of toxicity in mice and guinea-pigs treated with loaded MCHNPs. Stability test for six months showed acceptable changes in size, surface charge, and antigenicity for loaded MCH nanoparticles. Finally, in vivo immunogenicity study revealed greater adjuvant capability of MCH nanoparticles than others formulations. Our results showed MCH NPs can be used as a controlled and targeted vaccine delivery system.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Hepatitis B Virus Studies · Immunotherapy and Immune Responses · RNA Interference and Gene Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Medical Nanotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences

Razi Vaccine and Serum Research Institute, Agricultural Research, Education and Extension Organization (AREEO)

Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences

Regulatory Department, Production and Research Complex, Pasteur Institute of Iran

Nanobiomaterials Group, Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences

Department of Pharmaceutical Biomaterials and Medical Biomaterials Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences

Department of Immunology, Pasteur Institute of Iran

Stem Cell and Regenerative Medicine Institute, Tabriz University of Medical Sciences

Funding

Tehran University of Medical Sciences and Health Services

References (42)

Show source-provided references
1. 10.3109/21691401.2015.112962610.3109/21691401.2015.1129626 ↗
2. 10.1080/21691401.2016.118839610.1080/21691401.2016.1188396 ↗
3. 10.1080/21691401.2016.123311110.1080/21691401.2016.1233111 ↗
4. 10.3109/21691401.2013.76944710.3109/21691401.2013.769447 ↗
5. 10.1016/j.it.2008.09.00610.1016/j.it.2008.09.006 ↗
6. 10.1111/j.0818-9641.2004.01272.x10.1111/j.0818-9641.2004.01272.x ↗
7. 10.1016/j.nano.2013.03.00810.1016/j.nano.2013.03.008 ↗
8. 10.1080/21691401.2017.140811810.1080/21691401.2017.1408118 ↗
9. 10.1016/j.vaccine.2013.03.03010.1016/j.vaccine.2013.03.030 ↗
10. 10.1016/j.biopha.2017.03.03510.1016/j.biopha.2017.03.035 ↗
11. 10.17795/ijcp-419010.17795/ijcp-4190 ↗
12. 10.1080/21691401.2016.121685410.1080/21691401.2016.1216854 ↗
13. 10.1080/21691401.2017.133702210.1080/21691401.2017.1337022 ↗
14. 10.1080/21691401.2017.134787910.1080/21691401.2017.1347879 ↗
15. 10.3390/v907018610.3390/v9070186 ↗
16. Khanmohammadi M, Elmizadeh H, Ghasemi K. Investigation of size and morphology of chitosan nanoparticles used in drug delivery system employing chemometric technique. Iran J Pharm Res. 2015;14:665.
17. 10.3109/21691401.2014.94854810.3109/21691401.2014.948548 ↗
18. Al-So'od K. Interaction between low molecular weight chitosan and some types of drugs and insulin. Asian J Chem. 2012;24:3785–3790.
19. 10.3109/10731199.2012.74209510.3109/10731199.2012.742095 ↗
20. 10.1155/2014/52639110.1155/2014/526391 ↗
21. 10.1016/j.ijbiomac.2017.01.14710.1016/j.ijbiomac.2017.01.147 ↗
22. 10.1080/21691401.2016.127692210.1080/21691401.2016.1276922 ↗
23. 10.1080/21691401.2017.140811610.1080/21691401.2017.1408116 ↗
24. 10.1016/j.carbpol.2017.03.03110.1016/j.carbpol.2017.03.031 ↗
25. Raja Azalea D, Mohambed M, Joji S, et al. Design and evaluation of chitosan nanoparticles as novel drug carriers for the delivery of donepezil. Iran J Pharm Res. 2012;8:155–164.
26. Rezayat M. Preparation, characterization and stability investigation of chitosan nanoparticles loaded with the Echis carinatus snake venom as a novel delivery system. Arch Razi Institute 2015;70:269–277.
27. 10.1016/j.biologicals.2008.07.00710.1016/j.biologicals.2008.07.007 ↗
28. 10.1208/pt07025010.1208/pt070250 ↗
29. 10.59566/IJBS.2008.422110.59566/IJBS.2008.4221 ↗
30. Arora S, Lal S, Kumar S, et al. Comparative degradation kinetic studies of three biopolymers: chitin, chitosan and cellulose. Arch Appl Sci Res. 2011;3:188–201.
31. 10.1016/j.ijbiomac.2011.11.01910.1016/j.ijbiomac.2011.11.019 ↗
32. 10.2147/DDDT.S9965110.2147/DDDT.S99651 ↗
33. 10.3109/1061186X.2011.65412110.3109/1061186X.2011.654121 ↗
34. 10.1016/j.biomaterials.2016.12.03010.1016/j.biomaterials.2016.12.030 ↗
35. Ho HN, Tran TH, Tran TB, et al. Optimization and characterization of artesunate-loaded chitosan-decorated poly (D, L-lactide-co-glycolide) acid nanoparticles. J Nanomater. 2015;16:383.
36. 10.1158/1535-7163.MCT-05-054010.1158/1535-7163.MCT-05-0540 ↗
37. 10.2147/nano.2006.1.2.18110.2147/nano.2006.1.2.181 ↗
38. Aydin R, Pulat M. 5-Fluorouracil encapsulated chitosan nanoparticles for pH-stimulated drug delivery: evaluation of controlled release kinetics. J Nanomater. 2012;2012:42.
39. 10.1016/j.ijpharm.2015.08.05610.1016/j.ijpharm.2015.08.056 ↗
40. 10.1016/j.msec.2016.12.02710.1016/j.msec.2016.12.027 ↗
41. 10.4236/abb.2013.41214810.4236/abb.2013.412148 ↗
42. 10.1166/jnn.2015.925210.1166/jnn.2015.9252 ↗